{"entity":{"id":"nct05300269","kind":"trial","name":"SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer","aka":[],"tldr":"A phase 2 trial of Capecitabine, Oxaliplatin and Retlirafusp alfa in colorectal cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.","summary":"SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer is a phase 2 interventional study registered as NCT05300269 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 73 participants planned, started 2022-07-05 and due to reach its primary completion in 2024-07-31. Interventions recorded: SHR-1701；Capecitabine；Oxaliplatin.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05300269","url":"https://clinicaltrials.gov/study/NCT05300269"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["colorectal","rectal-cancer"],"sections":[],"technologies":["bispecific-antibody","checkpoint-inhibitor"],"targets":[],"drugs":["capecitabine","oxaliplatin","retlirafusp-alfa"],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct05300269-cancer-lett-2026"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05300269","phase":"2","setting":"SHR-1701 in Combination With Radiotherapy and Chemotherapy as Perioperative Treatment for Resectable Locally Advanced Rectal Cancer, an Open Label, Single-arm, Multicenter Phase II Trial","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","started":"2022-07-05","startedType":"actual","enrolled":73,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05300269/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"oxaliplatin","kind":"drug","name":"Oxaliplatin","route":"/drugs/oxaliplatin/"},{"id":"retlirafusp-alfa","kind":"drug","name":"Retlirafusp alfa","route":"/drugs/retlirafusp-alfa/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}],"paper":[{"id":"paper-nct05300269-cancer-lett-2026","kind":"paper","name":"Efficacy and safety of SHR-1701 combined with chemoradiotherapy as neoadjuvant treatment for locally advanced rectal cancer","route":"/key-papers/paper-nct05300269-cancer-lett-2026/"}]}}